Skip to main content

Table 4 Treatment-emergent adverse events occurring in ≥2 patients in any treatment group—52-week open label extension

From: First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

Adverse event

AAB-003

 

0.5 mg/kg to 0.5 mg/kg (N = 6)

1 mg/kg to 1 mg/kg (N = 3)

2 mg/kg to 2 mg/kg (N = 12)

4 mg/kg to 4 mg/kg (N = 10)

8 mg/kg to 8 mg/kg (N = 12)

Placebo to AAB-003* (N = 9)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Anxiety

0

0

2 (16.7)

0

1 (8.3)

0

Back pain

0

0

2 (16.7)

0

0

1 (11.1)

Depression

0

0

1 (8.3)

0

3 (25)

2 (22.2)

Dizziness

0

0

1 (8.3)

0

2 (16.7)

1 (11.1)

Contusion

0

0

0

0

2 (16.7)

0

Fall

1 (16.7)

2 (66.7)

0

0

1 (8.3)

0

Pollakiuria

0

0

2 (16.7)

0

0

0

  1. *Number of placebo subjects who transitioned to AAB-003 in the open label extension: 1 at 0.5 mg/kg, 1 at 1 mg/kg, 3 at 2 mg/kg, 1 at 4 mg/kg, and 3 at 8 mg/kg